Market Place
Sourcing Support
BridgeBio data show sustained benefit for achondroplasia drug
05 Jun 2024 //
BIOPHARMADIVE
BridgeBio: Durable Infigratinib Results In Achondroplasia Study
04 Jun 2024 //
GLOBENEWSWIRE
BridgeBio To Host Infigratinib Achondroplasia Phase 2 Data Call
03 Jun 2024 //
GLOBENEWSWIRE
For $100M, BridgeBio partners with Kyowa Kirin on infigratinib
07 Feb 2024 //
FIERCE PHARMA
BridgeBio Announces First Child Dosed in Phase 3 Clinical Trial for Infigratinib
13 Dec 2023 //
GLOBENEWSWIRE
LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib
25 Oct 2023 //
GLOBENEWSWIRE
BridgeBio Pharma Announces Positive Feedback for Phase 3 of Infigratinib
06 Sep 2023 //
GLOBENEWSWIRE
BridgeBio Presents Six Month Results from its Ph2 Cohort 5 Trial of Infigratinib
20 Jun 2023 //
GLOBENEWSWIRE
BridgeBio to Present Six Month Results from Phase 2 Study of Infigratinib
08 Jun 2023 //
GLOBENEWSWIRE
LianBio Announces Topline Results from Phase 2a Trial Evaluating Infigratinib
06 Jun 2023 //
GLOBENEWSWIRE
Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review
21 Dec 2021 //
GLOBENEWSWIRE
BridgeBio and LianBio Announce Patient Treated in Phase 2a Trial of Infigratinib
25 Aug 2021 //
BUSINESSWIRE
BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib
29 May 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.